Literature DB >> 9865840

Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.

S K Machen1, R A Prayson.   

Abstract

Pilocytic astrocytoma is an infrequently encountered, generally low-grade neoplasm. No study has extensively looked at both cyclin D1 and MIB-1 labeling indices in pilocytic astrocytoma and their relation to clinical outcome. This study retrospectively examines the clinicopathologic features of 48 patients with pilocytic astrocytoma including MIB-1 (cell proliferation marker) and cyclin D1 (protein that regulates progression from G1 to S phase of the cell cycle) immunohistochemistry. Of 48 patients (27 females and 21 males; mean age, 12.7 years; age range, 2 to 57 years), 26 initially underwent gross total resection; 17, subtotal resection; four, biopsy alone; in one patient, the extent of tumor resection was unknown. Histological features observed included Rosenthal fibers (83.3%), granular bodies (75%), vascular sclerosis (56.2%), vascular proliferation (56.2%), prominent nuclear pleomorphism (14.6%), necrosis (10.4%), and identifiable mitotic figures (2.1%). MIB-1 labeling indices (n=45) (positive staining tumor nuclei per 1,000 nuclei evaluated) ranged from 0 to 3.5% (mean, 0.6%); seven tumors had a labeling index greater than 1.0%. Cyclin D1 labeling indices (n=45) ranged from 0 to 0.8% (mean, 0.1%). Most tumors (N=29, 66.7%) had no immunostaining. At last known follow-up, 27 patients were alive with no evidence of disease (mean, 49.2 months), 17 patients were alive with evidence of disease (mean, 36.8 months), three died with tumor at 2, 22, and 156 months, and one patient was lost to follow-up. Eight patients had at least one tumor recurrence requiring additional surgery; seven of these patients had an initial subtotal resection. In summary, MIB-1 labeling indices were generally low (mean, 0.6%) and are reflective of the slow growth of the tumors. Cyclin D1 immunostaining does not appear to be significantly increased in pilocytic astrocytoma. Adverse outcome in patients with pilocytic astrocytoma may be related to extent of surgical resection and does not seem to correlate with histology, MIB-1 labeling indices, or cyclin D1 immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865840     DOI: 10.1016/s0046-8177(98)90023-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  Gamma Knife treatment of low-grade gliomas in children.

Authors:  Murat Şakir Ekşi; Baran Yılmaz; Akın Akakın; Zafer Orkun Toktaş; Ahmet Cemil Kaur; Mustafa Kemal Demir; Türker Kılıç
Journal:  Childs Nerv Syst       Date:  2015-07-15       Impact factor: 1.475

2.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Neuropathological spectrum of pilocytic astrocytoma: an Indian series of 120 cases.

Authors:  Ajay Malik; Prabal Deb; Mehar Chand Sharma; Chitra Sarkar
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

4.  Primary spinal pilocytic astrocytoma: clinical study with long-term follow-up in 16 patients and a literature review.

Authors:  Yong Jiang; Liang Lv; Senlin Yin; Peizhi Zhou; Shu Jiang
Journal:  Neurosurg Rev       Date:  2019-05-16       Impact factor: 3.042

Review 5.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

6.  Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.

Authors:  Valerie N Barton; Andrew M Donson; Diane K Birks; Bette K Kleinschmidt-DeMasters; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

7.  Sub-classification of low-grade cerebellar astrocytoma: is it clinically meaningful?

Authors:  Tine Bernhardtsen; Henning Laursen; Marie Bojsen-Møller; Flemming Gjerris
Journal:  Childs Nerv Syst       Date:  2003-09-30       Impact factor: 1.475

8.  Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes.

Authors:  Fausto J Rodriguez; Caterina Giannini; Yan W Asmann; Mukesh K Sharma; Arie Perry; Kathleen M Tibbetts; Robert B Jenkins; Bernd W Scheithauer; Shrikant Anant; Sarah Jenkins; Charles G Eberhart; Jann N Sarkaria; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2008-12       Impact factor: 3.685

9.  WT1 protein expression in astrocytic tumors and its relationship with cellular proliferation index.

Authors:  Parvin Mahzouni; Zahra Meghdadi
Journal:  Adv Biomed Res       Date:  2013-03-14

10.  Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival.

Authors:  Hidehiro Takei; Subashini T Yogeswaren; Kwong-Kwok Wong; Vidya Mehta; Murali Chintagumpala; Robert C Dauser; Ching C Lau; Adekunle M Adesina
Journal:  J Neurooncol       Date:  2007-08-10       Impact factor: 4.506

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.